Tesa10 + IP5 (Tesamorelin 10mg + Ipamorelin 5mg Blend)

Industry shorthand explanation:

Tesa = Tesamorelin (GHRH analog)

IP5 = Ipamorelin 5mg (GHRP agonist)

This dual-peptide lyophilized blend combines Tesamorelin & Ipamorelin inside one vial.

1. Basic Overview

Individual Peptide Information

• CAS Number: 218949-48-5
• Molecular Weight: 5135.9 Da
• Classification: Synthetic Growth Hormone-Releasing Hormone (GHRH) analog
• Core trait: Stimulates pituitary pulsatile endogenous GH secretion; famous for visceral adipose tissue lipolysis research.

• CAS Number: 170851-70-4
• Molecular Weight: 711.86 Da
• Classification: Selective Growth Hormone Releasing Peptide (GHRP) agonist
• Core trait: Stimulates GH release without significant elevation of cortisol or prolactin.

Blend Profile: Tesa10+IP5

• Standard Specification: 10mg Tesamorelin + 5mg Ipamorelin per single vial
• Form: Lyophilized white crystalline powder
• Synergy Principle:

  GHRH (Tesamorelin) + GHRP (Ipamorelin) work via two separate receptor pathways to amplify growth hormone pulsatile release. Together they achieve stronger GH & IGF-1 elevation compared to single-peptide administration.

2. Mechanism of Action

1. Tesamorelin (GHRH Pathway)

   Binds pituitary GHRH receptors, drives natural, pulsatile growth hormone synthesis and secretion. Primarily researched for visceral fat breakdown, lipid metabolism regulation and body composition modulation.

2. Ipamorelin (GHRP Pathway)

   Activates ghrelin receptors in the pituitary gland to trigger GH release. It exhibits minimal impact on adrenocorticotropic hormone, cortisol and prolactin levels.

3. Combined Synergistic Effects

• Amplified pulsatile GH secretion, superior to single peptide research models
• Enhanced lipolysis, especially targeting visceral abdominal fat
• Improved connective tissue repair, muscle maintenance research
• Balanced endocrine profile with lower risk of excess cortisol elevation compared to other GHRP combinations

3. Main Research Applications

• Body composition & visceral fat metabolism research
• Endocrine and growth hormone pathway pharmacology studies
• Skeletal muscle maintenance & soft tissue recovery experiments
• Aging, longevity and metabolic homeostasis research
• Comparative studies: Single GHRH / single GHRP vs dual agonist blends
• Lipid profile regulation and insulin sensitivity experimental models

4. Reconstitution Instructions (Lyophilized Blend Vial)

1. Let vial reach room temperature; disinfect rubber stopper with alcohol wipe.
2. Slowly inject Bacteriostatic Water along the inner glass wall. Avoid direct impact onto lyophilized powder.

Recommended mixing scheme: Add 3mL BAC water

Final concentration:

Tesamorelin: 3.33 mg / mL

Ipamorelin: 1.67 mg / mL

3. Gently rotate the vial to dissolve powder. DO NOT shake violently to prevent peptide aggregation and degradation. Qualified solution is clear and colourless.
4. Storage Requirements

• Unreconstituted lyophilized powder: Hermetically sealed, stored at -20°C, protected from light. Stable for up to 24 months.
• Reconstituted peptide solution: Refrigerate 2°C ~ 8°C, stable within 28 days. Do not freeze reconstituted liquid.

Special Note: Tesamorelin is prone to aggregation. Avoid repeated temperature fluctuations.

5. Research Administration Protocols

Primary Route: Subcutaneous Injection

Reference Experimental Dosage (Blend whole-vial ratio)

• Low starting tolerance dose: 0.3mL solution once daily
• Standard experimental dose: 0.4–0.6mL solution once daily
• Max researched dose: 0.7mL solution once daily
• Recommended timing: Evening, 90–120 minutes after last meal (consistent with GH natural circadian rhythm)
• Injection site: Lower abdomen, anterior thigh or upper arm; rotate injection positions regularly.

Reference Experimental Cycle

6. Precautions & Observed Adverse Reactions

1. Pure laboratory research compound. Not authorized for human therapeutic use.
2. Strict aseptic technique required during reconstitution to prevent microbial contamination.
3. Discard solution immediately if turbidity, precipitation or discoloration appears.
4. Common dose-dependent mild observed effects: transient redness/itching at injection site, mild temporary bloating.
5. Avoid pairing with other GH secretagogues simultaneously unless defined by experimental protocol.
6. Long-term high-dose safety data remains limited; all research must comply with laboratory ethics standards.

Short Version (For Product Page / Customer Direct Message)

Tesa10 + IP5 (Tesamorelin 10mg + Ipamorelin 5mg Blend)

Reconstitution

Reference Subcutaneous Research Dosage